{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:03Z","timestamp":1793035863437,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bmcl.2022.128891","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T12:39:56Z","timestamp":1657715996000},"page":"128891","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis"],"prefix":"10.1016","volume":"73","author":[{"given":"Silvana","family":"Leit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy R.","family":"Greenwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayan","family":"Mondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Carriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine C.","family":"Harriman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Kennedy-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Kapeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon P.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela V.","family":"Toms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mee","family":"Shelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald T.","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Westlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"McElwee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig E.","family":"Masse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128891_b0005","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2217\/imt-2021-0096","article-title":"TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases","volume":"13","author":"Gonciarz","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bmcl.2022.128891_b0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","article-title":"Kinase inhibition in autoimmunity and inflammation","volume":"20","author":"Zarrin","year":"2021","journal-title":"Nat Rev Drug Disc"},{"key":"10.1016\/j.bmcl.2022.128891_b0015","first-page":"1409","article-title":"TYK2 inhibition and its potential in the treatment of chronic inflammatory immune diseases","volume":"1910","author":"Ghoreschi","year":"2021","journal-title":"J Deutchen Dermat Gesell"},{"key":"10.1016\/j.bmcl.2022.128891_b0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nature11582","article-title":"Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease","volume":"491","author":"Jostins","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128891_b0025","doi-asserted-by":"crossref","first-page":"e0122271","DOI":"10.1371\/journal.pone.0122271","article-title":"TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of pleiotropic effects on non-autoimmune complex traits","volume":"10","author":"Diogo","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bmcl.2022.128891_b0030","doi-asserted-by":"crossref","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Science Transl Med"},{"key":"10.1016\/j.bmcl.2022.128891_b0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.22631\/rr.2018.69997.1057","article-title":"Association of TYK2 rs34536443 polymorphism with Susceptibility to Systemic Lupus Erythematous in the Iranian Population","volume":"3","author":"Faezi","year":"2018","journal-title":"Rheumatol Res"},{"key":"10.1016\/j.bmcl.2022.128891_b0040","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/brain\/awr010","article-title":"Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility","volume":"134","author":"Couturier","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.bmcl.2022.128891_b0045","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.1203118","article-title":"Two rare disease-associated TYK2 variants are catalytically impaired but signaling competent","volume":"190","author":"Li","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128891_b0050","first-page":"7043","article-title":"The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells","volume":"8","author":"Enerback","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2022.128891_b0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and janus kinase-signal tranducer and activator of transcription signalling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bmcl.2022.128891_b0060","first-page":"1","article-title":"TYK2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors","volume":"Apr. 30","author":"Jo","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.bmcl.2022.128891_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2021.685280","article-title":"From science to success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and related chronic inflammatory diseases","volume":"12","author":"Hromadova","year":"2021","journal-title":"Front Genetics"},{"key":"10.1016\/j.bmcl.2022.128891_b0070","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition of psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"New Eng J Med"},{"key":"10.1016\/j.bmcl.2022.128891_b0075","first-page":"1","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmcl.2022.128891_b0080","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543776.2019.1567713","article-title":"Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2015\u20132018)","volume":"29","author":"He","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2022.128891_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127862","article-title":"Small molecule approaches to treat autoimmune and inflammatory diseases (Part 1): Kinase inhibitors","volume":"38","author":"Zheng","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128891_b0090","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1021\/acs.jmedchem.0c01468","article-title":"Discovery of 3-(4-(2-((1H-indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-1-yl)propanenitrile derivatives as selective TYK2 inhibitors for the treatment of inflammatory bowel disease","volume":"64","author":"Zhang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0095","first-page":"1","article-title":"Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019\u20132021)","volume":"Jan 31","author":"de Turiso","year":"2022","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.bmcl.2022.128891_b0100","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bmcl.2022.128891_b0105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1756-8722-6-79","article-title":"Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing","volume":"6","author":"Mesa","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bmcl.2022.128891_b0110","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2020.1780120","article-title":"JAK selectivity: more precision less troubles","volume":"14","author":"Roda","year":"2020","journal-title":"Exp Rev Gastroent Hepat"},{"key":"10.1016\/j.bmcl.2022.128891_b0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.sbi.2016.10.007","article-title":"Accelerating drug discovery through tight integration of expert molecular design and predictive scoring","volume":"43","author":"Abel","year":"2017","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bmcl.2022.128891_b0120","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0125","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0130","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: Discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0135","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: A clinical TYK2 inhibitor that binds to TYK2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0140","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1021\/ja512751q","article-title":"Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field","volume":"137","author":"Wang","year":"2015","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2022.128891_b0145","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0150","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1021\/acs.jmedchem.6b00131","article-title":"WScore: A Flexible and Accurate Treatment of Explicit Water Molecules in Ligand-Receptor Docking","volume":"59","author":"Murphy","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2022.128891_b0155","doi-asserted-by":"crossref","unstructured":"Calculated ALogP performed as described in Ghose, A. K.; Viswanadhan, V. N.; Wendoloski, J. J., Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Usine Fragmental Methods: An Analysis of ALOGP and CLOGP Methods. J. Phys. Chem. 1998, 102, 3762-3772.","DOI":"10.1021\/jp980230o"},{"key":"10.1016\/j.bmcl.2022.128891_b0160","doi-asserted-by":"crossref","unstructured":"Liang, J.; Abbema, A. v.; Balazs, M.; Barnett, K.; Berezhkovsky, L.; Blair, W.; Chang, C.; Delarosa, D.; DeVoss, J.; Driscoll, J.; Eigenbrot, C.; Ghilardi, N.; Gibbons, P.; Halladay, J.; Johnson, A.; Kohli, P. B.; Lai, Y.; Liu, Y.; Lyssikatos, J.; Mantik, P.; Menghrajani, K.; Murray, J.; Peng, I.; Sambrone, A.; Shia, S.; Shin, Y.; Smith, J.; Sohn, S.; Tsui, V.; Ultsch, M.; Wu, L. C.; Xiao, Y.; Yang, W.; Young, J.; Zhang, B.; Zhu, B.-Y.; Magnuson, S. Lead Optimization of a 4-Aminopyridine Benzamide Scaffold to Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors. J. Med. Chem. 2013, 56, 4521-4536.","DOI":"10.1021\/jm400266t"},{"key":"10.1016\/j.bmcl.2022.128891_b0165","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.1202859","article-title":"A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors","volume":"191","author":"Sohn","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128891_b0170","unstructured":"See supplementary information for detailed procedures, protocols, and data sets."},{"key":"10.1016\/j.bmcl.2022.128891_b0175","doi-asserted-by":"crossref","unstructured":"Mondal S.; Tresadern G.; Greenwood J.; Kim B.; Kaus J.; Wirtala M.; Steinbrecher, T.; Wang, L.; Masse, C.; Farid, R.; Abel, R., A Free Energy Perturbation Approach to Estimate the Intrinsic Solubilities of Drug-like Small Molecules. ChemRxiv. Cambridge: Cambridge Open Engage, 2019.","DOI":"10.26434\/chemrxiv.10263077.v1"},{"key":"10.1016\/j.bmcl.2022.128891_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bmcl.2022.128891_b0185","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4049\/jimmunol.1301513","article-title":"Therapeutic Efficacy of Suppressing the JAK\/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis","volume":"192","author":"Liu","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128891_b0190","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int Immunol"},{"key":"10.1016\/j.bmcl.2022.128891_b0195","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.bmcl.2017.08.022","article-title":"Identification of an imidazapyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model","volume":"27","author":"Liang","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2022.128891_b0200","doi-asserted-by":"crossref","first-page":"181","DOI":"10.4049\/jimmunol.1003244","article-title":"Involvement of Tyrosine Kinase-2 in Both the IL-12\/Th1 and IL-23\/Th17 Axes In Vivo","volume":"187","author":"Ishizaki","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128891_b0205","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.4049\/jimmunol.1400205","volume":"193","author":"Works","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.bmcl.2022.128891_b0210","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c00073","article-title":"Principles of Kinase Allosteric Inhibition and Pocket Validation","author":"Pan","year":"2022","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X22003675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:20Z","timestamp":1760773580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X22003675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":42,"alternative-id":["S0960894X22003675"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128891","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128891","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"128891"}}